<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515629</url>
  </required_header>
  <id_info>
    <org_study_id>R2810-ONC-16111</org_study_id>
    <secondary_id>2017-001041-27</secondary_id>
    <nct_id>NCT03515629</nct_id>
  </id_info>
  <brief_title>REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer</brief_title>
  <official_title>A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the progression-free survival (PFS) of&#xD;
      REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as&#xD;
      REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet chemotherapy plus&#xD;
      ipilimumab combination therapy (hereinafter referred to as &quot;REGN2810/chemo/ipi&quot;) with&#xD;
      standard-of-care pembrolizumab monotherapy in the first-line treatment of patients with&#xD;
      advanced squamous or non-squamous non-small cell lung cancer (NSCLC) whose tumors express&#xD;
      programmed death ligand 1 (PD-L1) in ≥50% of tumor cells. The key secondary objectives of the&#xD;
      study are to compare the overall survival (OS) of REGN2810/ipi and REGN2810/chemo/ipi with&#xD;
      pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or&#xD;
      non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells and to compare the&#xD;
      overall response rate (ORR) of REGN2810/ipi and REGN2810/chemo/ipi with pembrolizumab&#xD;
      monotherapy in the first-line treatment of patients with advanced squamous or non-squamous&#xD;
      NSCLC whose tumors express PD-L1 in ≥50% of tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">July 29, 2021</completion_date>
  <primary_completion_date type="Actual">July 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS as assessed by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessments</measure>
    <time_frame>Up to 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Core 30 Questionnaire)</measure>
    <time_frame>Up to 32 months</time_frame>
    <description>As measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) four-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Lung Cancer 13 Questionnaire)</measure>
    <time_frame>Up to 32 months</time_frame>
    <description>As measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as &quot;not at all&quot; and 4 rated as &quot;very much&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2810/ipi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN2810/ipi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2810/chemo/ipi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN2810/chemo/ipi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810/ipi</intervention_name>
    <description>REGN2810 plus ipilimumab</description>
    <arm_group_label>REGN2810/ipi</arm_group_label>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810/chemo/ipi</intervention_name>
    <description>REGN2810 plus chemotherapy plus Ipilimumab</description>
    <arm_group_label>REGN2810/chemo/ipi</arm_group_label>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Reference drug administered IV infusion</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically documented squamous or non-squamous&#xD;
             NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment&#xD;
             for recurrent or metastatic NSCLC&#xD;
&#xD;
          2. Availability of an archival (≤5 months) or on-study obtained formalin-fixed,&#xD;
             paraffin-embedded tumor tissue sample which has not previously been irradiated&#xD;
&#xD;
          3. Expression of PD-L1 in ≥50% of tumor cells determined by the commercially available&#xD;
             assay performed by the central laboratory&#xD;
&#xD;
          4. At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a&#xD;
             previously irradiated field if there is documented (radiographic) disease progression&#xD;
             in that site&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1&#xD;
&#xD;
          6. Anticipated life expectancy of at least 3 months&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime&#xD;
&#xD;
          2. Active or untreated brain metastases or spinal cord compression&#xD;
&#xD;
          3. Patients with tumors tested positive for Epidermal growth factor receptor (EGFR) gene&#xD;
             mutations, Anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene&#xD;
             receptor tyrosine kinase(ROS1) fusions&#xD;
&#xD;
          4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed&#xD;
             consent&#xD;
&#xD;
          5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing&#xD;
             pneumonia), of active, noninfectious pneumonitis that required immune-suppressive&#xD;
             doses of glucocorticoids to assist with management, or of pneumonitis within the last&#xD;
             5 years&#xD;
&#xD;
          6. Ongoing or recent evidence of significant autoimmune disease that required treatment&#xD;
             with systemic immunosuppressive treatments, which may suggest risk of immune-related&#xD;
             treatment-emergent adverse events (irTEAEs)&#xD;
&#xD;
          7. Previous treatment with idelalisib at any time (ZYDELIG®)&#xD;
&#xD;
          8. Patients with a condition requiring corticosteroid therapy (&gt;10 mg prednisone/day or&#xD;
             equivalent) within 14 days of randomization&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IIIB</keyword>
  <keyword>Stage IV</keyword>
  <keyword>Non-squamous NSCLC</keyword>
  <keyword>Squamous NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

